A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical pharmacology and therapy

• Publication date

  2006-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clpt.2006.06.009PMID 17015052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

  2006cited by this paper
• Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism

  2006cited by this paper
• Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

  2006cited by this paper
• Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements

  2006cited by this paper
• CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese.

  2006cited by this paper
• Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin

  2006cited by this paper
• Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

  2006cited by this paper
• Allele and genotype frequencies of CYP2C9 in a Korean population.

  2005cited by this paper
• The pharmacogenetics of coumarin therapy.

  2005cited by this paper
• CYP2C9 Haplotype Structure in European American Warfarin Patients and Association with Clinical Outcomes

  2005cited by this paper
• Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype

  2005cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

  2005cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• Common VKORC1 and GGCX polymorphisms associated with warfarin dose

  2005cited by this paper
• Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

  2005cited by this paper
• Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

  2004cited by this paper
• CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences

  2004cited by this paper
• Novel CYP2C9 genetic variants in asian subjects and their influence on maintenance warfarin dose

  2004cited by this paper
• Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin

  2003cited by this paper
• Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients

  2003cited by this paper
• Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism

  2003cited by this paper
• The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance

  2002cited by this paper
• Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

  2001cited by this paper
• Interindividual variability in sensitivity to warfarin‐Nature or nurture?

  2001cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range

  2001cited by this paper
• Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

  2001cited by this paper
• Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

  2000cited by this paper
• A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients.

  2000cited by this paper
• Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.

  2000cited by this paper
• A randomized trial comparing 5-mg and 10-mg warfarin loading doses.

  1999influential reference
• A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

  1999cited by this paper
• Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

  1998cited by this paper
• Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

  1995cited by this paper
• Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

  1992cited by this paper
• Effect of age and gender on the activity of human hepatic CYP3A.

  1992cited by this paper
• Flexible induction dose regimen for warfarin and prediction of maintenance dose.

  1984cited by this paper
• Control of Norway rats with residual rodenticide warfarin.

  1950cited by this paper

• Warfarin Pharmacogenomics in the Era of Precision Medicine: Persistent Underrepresentation of Non-European Ancestries and Implications for Global Health Equity

  2025cites this paper
• Establishment of Acenocoumarol Pharmacogenetic Algorithm Including CYP2C9 and VKORC1 Genotypes in Bulgarian Patients Treated with Coumarin Anticoagulants

  2025cites this paper
• Quantitative Comparison of the Predictive Accuracy of Warfarin Pharmacogenetic Dosing Algorithms Derived From Population Data of Different Ethnicities in the Chinese Population

  2025influential citation
• Validating two international warfarin pharmacogenetic dosing algorithms for estimating the maintenance dose for patients in Singapore.

  2024cites this paper
• Ethnic Diversity and Warfarin Pharmacogenomics

  2022cites this paper
• Pharmacogenetic algorithm for predicting daily dose of warfarin in Caucasian patients of Czech origin

  2020cites this paper
• Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype‐Based Dosing Algorithms

  2020cites this paper
• Pharmacogenetic testing: 5 Questions

  2020cites this paper
• Evolutionary Ensemble Learning Algorithm to Modeling of Warfarin Dose Prediction for Chinese

  2019cites this paper
• Pharmacogenetics of Warfarin in a Diverse Patient Population

  2019cites this paper
• Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds

  2019cites this paper
• PHARMACOGENETIQUE DE L’ACENOCOUMAROL : LES GENES IMPLIQUES DANS LA VARIABILITE DE LA REPONSE ET PROPOSITION D’UN ALGORITHME PREDICTIF DE LA DOSE POUR LA POPULATION MAROCAINE

  2019cites this paper
• Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants

  2018cites this paper
• Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial

  2018influential citation
• Comparative performance of pharmacogenetics‐based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population

  2018cites this paper
• The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.

  2017cites this paper
• Neue Einsichten in die orale Antikoagulations-

  2017cites this paper
• Evolutionary learning-based modeling for warfarin dose prediction in Chinese

  2017cites this paper
• Swarm ANN/SVR-Based Modeling Method for Warfarin Dose Prediction in Chinese

  2017cites this paper
• Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population

  2017cites this paper
• Engaging Hmong adults in genomic and pharmacogenomic research: Toward reducing health disparities in genomic knowledge using a community-based participatory research approach

  2017cites this paper
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†

  2017cites this paper
• Fundamentals of Pharmacogenetics in Personalized, Precision Medicine.

  2016cites this paper
• VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance

  2016cites this paper
• Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.

  2015cites this paper
• VKORC1 and CYP2C9 genotypic data-based dose prediction alone does not accurately predict warfarin dose requirements in some Malaysian patients.

  2015cites this paper
• Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs

  2015cites this paper
• Ambulatory Warfarin Management

  2015cites this paper
• Short report Open Access

  2015cites this paper
• Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation

  2015cites this paper
• Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements

  2015cites this paper
• Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database

  2015cites this paper
• Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients.

  2015cites this paper
• VKORC1 and CYP2C9 genotype distribution in Asian countries.

  2014cites this paper
• Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population

  2014cites this paper
• A New Nested Allele-Specific Multiplex Polymerase Chain Reaction Method for Haplotyping of VKORC1 Gene to Predict Warfarin Sensitivity

  2014cites this paper
• An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population

  2014cites this paper
• Global epidemiology of atrial fibrillation

  2014cites this paper
• Pharmacogenomics of Warfarin

  2014cites this paper
• Study Of Genetic And Pharmacokinetic Issues Related To Efficacy And Toxicity Of Warfarin In Pakistani Subjects

  2014cites this paper
• [Effect of genetic variations on adjusting of warfarin dose].

  2014cites this paper
• Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

  2014cites this paper
• Willingness-to-pay and preferences for warfarin pharmacogenetic testing in Chinese warfarin patients and the Chinese general public.

  2013cites this paper
• Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population

  2013cites this paper
• Development of predictive models for estimating warfarin maintenance dose based on genetic and clinical factors.

  2013cites this paper
• Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.

  2013cites this paper
• A systematic review on pharmacogenetics in cardiovascular disease Is it ready for clinical application ?

  2013cites this paper
• Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms

  2013cites this paper
• Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.

  2013cites this paper
• EFFECT OF CYP 2 C 9 AND VKORC 1 GENETIC POLYMORPHISMS ON WARFARIN DOSE REQUIREMENT IN SOUTH INDIAN POPULATION

  2013cites this paper
• Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.

  2013cites this paper
• Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients.

  2013cites this paper
• Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population

  2013cites this paper
• 1 (VKORC1) affects gene expression and warfarin dose requirement Regulatory polymorphism in vitamin K epoxide reductase complex subunit

  2013cites this paper
• EFFECT OF CYP2C9 AND VKORC1 GENETIC POLYMORPHISMS ON WARFARIN DOSE REQUIREMENT IN SOUTH INDIAN POPULATION

  2013cites this paper
• Genetic and pharmacogenetic determinants of cardiovascular disease

  2013cites this paper
• Personalised treatment with oral anticoagulant drugs : clinical and economic issues

  2013cites this paper
• Towards optimal dosing of coumarin derivatives: the role of pharmacogenetics

  2013cites this paper
• Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin

  2012cites this paper
• Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis

  2012cites this paper
• The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.

  2012cites this paper
• Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation

  2012cites this paper
• The pharmacogenetics of the response to warfarin in Chinese.

  2012cites this paper
• Study of polymorphism frequency of 1639G> A gene from VKORC1 in patients with cardiovascular disorders in the northwestern area of Iran

  2012cites this paper
• Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients

  2012cites this paper
• Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients

  2012cites this paper
• Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study

  2011cites this paper
• Application of Pharmacometric Methods to Improve Pediatric Drug Development

  2011cites this paper
• Clinical applications of pharmacogenomics guided warfarin dosing

  2011cites this paper
• Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia

  2011cites this paper
• Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multiethnic Asian population

  2011cites this paper
• Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.

  2011cites this paper
• The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs

  2011cites this paper
• Pharmacogenetic Aspects and Drug Interactions in Anticoagulation Therapy with Coumarins

  2011cites this paper
• Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients

  2011cites this paper
• Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort.

  2011cites this paper
• Genotype-Based Dosing Algorithms for Warfarin Therapy

  2011cites this paper
• Risk modeling strategies for pharmacogenetic studies.

  2011cites this paper
• Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.

  2011cites this paper
• The Statin Response Gene: KIF6

  2011influential citation
• Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations

  2011cites this paper
• Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population

  2011cites this paper
• Optimization of Anticoagulation with Warfarin for Stroke Prevention: Pharmacogenetic Considerations

  2011cites this paper
• Étude pharmacogénomique sur l’utilisation de la warfarine en pratique clinique réelle

  2011cites this paper
• Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments.

  2010cites this paper
• Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

  2010cites this paper
• Surgical innovations arising from the Iraq and Afghanistan wars.

  2010cites this paper
• Pharmacogenetically tailored treatments for heart disease.

  2010cites this paper
• Pharmacogenetics of oral anticoagulant therapy.

  2010cites this paper
• [Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study].

  2010cites this paper
• Comparative performance of gene‐based warfarin dosing algorithms in a multiethnic population

  2010cites this paper
• Pharmacogenetics of warfarin.

  2010cites this paper
• [Which of algorithms of warfarin dosing based on results of pharmacogenetic testing is suitable for patients in Russia].

  2010cites this paper
• Predicting warfarin dose

  2010cites this paper
• CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.

  2010cites this paper
• Implementing genotype-guided antithrombotic therapy.

  2010cites this paper
• Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.

  2010cites this paper
• Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.

  2010cites this paper
• Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

  2010cites this paper
• Patient Factors That Influence Warfarin Dose Response

  2010cites this paper